{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:48:40Z","timestamp":1786373320070,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23-HL133843"],"award-info":[{"award-number":["K23-HL133843"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-DK007006"],"award-info":[{"award-number":["T32-DK007006"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.2215\/cjn.09720822","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T11:29:21Z","timestamp":1662722961000},"page":"1436-1438","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Resistant Hypertension in Chronic Kidney Disease"],"prefix":"10.2215","volume":"17","author":[{"given":"Rachel","family":"Shulman","sequence":"first","affiliation":[{"name":"Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-079X","authenticated-orcid":false,"given":"Jordana B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: Core curriculum 2019","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"B3-20241015","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the Chronic Renal Insufficiency Cohort study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/HYPERTENSIONAHA.120.15064","article-title":"Adverse health outcomes associated with refractory and treatment-resistant hypertension in the Chronic Renal Insufficiency Cohort","volume":"77","author":"Buhnerkempe","year":"2021","journal-title":"Hypertension"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2215\/CJN.04110422","article-title":"Prevalence of apparent treatment-resistant hypertension in chronic kidney disease in two large US health care systems.","volume":"17","author":"An","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.ajkd.2021.09.013","article-title":"KDOQI US commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD","volume":"79","author":"Drawz","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for Primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.09720822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:44Z","timestamp":1786369484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.09720822"}},"subtitle":["A Burden unto Itself"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09720822","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}